NCT06427681尚未招募早期 1 期
An Open-label, Randomized, Single-dose, Two-period Cross-over Study to Evaluate the Relative Bioavailability Between BH006 for Injection Per the Intended Dosage Regimen and Fosaprepitant and Palonosetron in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 尚未招募
- 入组人数
- 40
- 主要终点
- Pharmacokinetic Analysis
研究概览
简要总结
The study is an open label, randomized, balanced, two period, two sequence, crossover, single dose, relative bioavailability study in healthy subjects.Each subject, meeting all the inclusion criteria and none of the exclusion criteria, will receive test product or reference product in a crossover manner based on randomization schedule. A balance between T-R and R-T randomization sequence will be ensured using statistical techniques. Blood samples for PK assessment will be collected prior to and after start of intravenous infusion on Day 1 (Period I), Day 15 (Period II).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Willing and able to provide signed and dated informed consent prior to any study-related procedures.
- •Willing and able to comply with all study procedures.
- •Subjects and their spouses must agree to use adequate contraception 14 days prior to the first dose, for the duration of study participation, and for 6 months following completion of therapy.
- •Healthy subjects of either gender, ≥18 years of age, or ≤ 55 years of age.
- •Have a body weight (BW) of ≥ 45.0 kg(female) / ≥ 50.0 kg(male) and 18 ≤ body mass index (BMI) ≤ 28 kg/m
- •Subjects had normal vital signs (T: 35.9~37.6℃; P: 50~100 beats/min; BP: 90~139mmHg/60~89mmHg, all including critical values) and good organ function prior to enrollment:
- •12-ECG: QTc <450 milliseconds for males and <470 milliseconds for females;
- •Platelets ≥ 100 × 109/L; neutrophil count ≥ 1.5 × 109/L; hemoglobin ≥ 110 g/L;
- •Alanine aminotransferase, aspartate aminotransferase and bilirubin ≤ ULN;
- •Subjects with abnormal values on physical examination and the rest of the laboratory tests were also enrolled if the investigator determined that the abnormality was not clinically significant in the context of past medical history.
排除标准
- •Those who are known to be allergic to the investigational drug, its excipients, or similar drugs, or those who suffer from allergic diseases or belong to an allergic constitution (such as allergies to two or more drugs, food, or pollen).
- •Those who have a history of clinically serious disease and have not been cured, or those who currently have a disease that may significantly affect the PK or safety evaluation of the study drug.
- •Those with abnormal and clinically significant vital signs, 12-ECG, and clinical laboratory tests.
- •Major surgery within 90 days prior to study entry; minor surgery within 2 weeks prior to study entry.
- •Subjects who have received a vaccination within 30 days prior to the first dose.
- •Subjects who have used or using any drug within 30 days prior to the first dose that may have a significant impact on the PK or safety evaluation of this study drug, including, but not limited to, CYP3A4 inhibitors/agonists, drugs that may alter activity of drug metabolizing enzyme of liver.
- •Subjects who have participated in and used any clinical trial drug within 90 days prior to the first dose, or plan to participate in other clinical trials during this study.
- •Those with a history of alcohol abuse, or regular drinkers within 90 days prior to the first dose (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine), or those who could not abstain during the test, or had a positive alcohol breath test. (1 unit = 1 unit of alcohol = about 285 mL of beer or about 100 mL of red wine or about 25 mL of beverage containing 40% (v/v) alcohol).
- •Subjects who are addicted to tobacco (more than 5 cigarettes or equivalent per day) within 30 days prior to the first dose, or who were unable to quit smoking during the trial.
- •Subjects who have lost/donated more than 450 mL of blood (except physiological blood loss in females) within 90 days prior to the first dose, or who have received a blood transfusion or used a blood product, or who plan to donate blood during the trial or within 30 days of the end of the trial.
- •Subjects who have taken a special diet (including pitaya, mango, grapefruit, etc.) or have had strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, or excretion within 14 days prior to the first dose.
- •Consumption of food or beverages containing alcoholic products or caffeine or xanthine within 48 hours before the first dose.
- •Subjects have a history of drug abuse within the past five years or a positive drug abuse screen.
- •Subjects have presence of Hepatitis B surface antigen (HBsAg) or a Positive Hepatitis C antibody test result, or positive human immunodeficiency virus (HIV) antibody test, or Positive test for syphilis spirochete antibodies at screening.
- •Female subjects who are pregnant or breastfeeding, or have a positive blood pregnancy test result at screening.
- •Subjects have other clinical significant findings within the 12 months prior to screening that indicate clinically significant disease of the following (including, but not limited to, gastrointestinal, renal, hepatic, neurological, haematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular disorders); and suffering from any condition that increases the risk of haemorrhage such as haemorrhoids, acute gastritis, or gastric and duodenal ulcers, intractable constipation.
- •Subjects who have a history of needle sickness, blood sickness or have a problem in collecting blood.
- •Subjects who have an acute illness or concomitant medication from the screening phase until the first dose.
- •Subjects who are engaged in high-altitude work, vehicle driving and other operators of machinery associated with danger.
- •Subjects have other issues that may lead to non-compliance or be unsuitable for inclusion by investigators' judgement.
研究组 & 干预措施
BH006 for injection
Experimental
150 mg fosaprepitant/0.25 mg palonosetron intravenously 30 minutes (±1 minute)
干预措施: BH006 for injection (Drug)
Fosaprepitant for injection+Palonosetron hydrochloride injection
Active Comparator
Fosaprepitant for injection：150 mg fosaprepitant intravenously 30 minutes (±1 minute) ; Palonosetron hydrochloride injection： 0.25 mg palonosetron in 5 mL (0.05 mg/mL) infusion time is 30 seconds (﹢5seconds) .
干预措施: Fosaprepitant for injection+Palonosetron hydrochloride injection (Drug)
结局指标
主要结局
Pharmacokinetic Analysis
时间窗: Period I&Period II：pre-dose to 168.000 hours after starting the infusion.
The PK endpoints will be studied and assessed by PK parameters for aprepitant :Maximum Concentration (Cmax).
次要结局
- Pharmacokinetic Analysis(Period I&Period II：pre-dose to 168.000 hours after starting the infusion.)
研究者
相似试验
已完成
1 期
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor MalignanciesCancerNCT01725100GlaxoSmithKline80
尚未招募
1 期
A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy SubjectsHealth SubjectsNCT06325761Shouyao Holdings (Beijing) Co. LTD28
Unknown
1 期
Pharmacokinetic Assessment of Simultaneous Administration of Clopidogrel and AspirinCoronary Artery DiseaseNCT01388660Ajou University School of Medicine60
已完成
1 期
Absolute Bioavailability Of BosutinibHealthyNCT02192294Pfizer14
已完成
1 期
A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy VolunteersHealthyNCT02058277Pfizer20